Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis [1]

AIDS

Volumn 17, Issue 4, 2003, Pages 637-638

  Oliva, Jesús ^a   Moreno, Santiago ^a   Sanz, Jesús ^b   Ribera, Esteban ^c   Pérez Molina, José A Ò ^d   Rubio, Rafael ^e   Casas, Esperanza ^f   Mariño, Ana ^g  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^g Universidad de La Coruña   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NEVIRAPINE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AIDS RELATED COMPLEX; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIVER TOXICITY; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD;

EID: 0037423827     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200303070-00024     Document Type: Letter

References (9)

1. Sterling TR, Alwood K, Gachuchi R, Coggin W, Blazes D, Bishai WR, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999, 13:1899-1904.
2. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998, 47 (RR-20):36-42.
3. Moreno S, Podzamczer D, Blazquez R, Iribarren JA, Ferrer E, Reparaz J, et al. Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin. AIDS 2001, 15:1185-1187
4. Veldkamp AI, Hoetelmans RM, Beijnen JH, Mulder JW, Meenhorst PL. Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 1999, 29:1586.
5. Lopez-Cortes LF, Ruiz R, Viciana P, Alarcón A, Leon E, Sarasa M, et al. Pharmacokinetic interactions between rifampin and efavirenz in patients with tuberculosis and HIV infection. In: VIIIth Conference on Retroviruses and Opportunistic Infections. Chicago, USA, February 2001 [Abstract 32].
6. Dean GL, Back DJ, de Ruiter A. Impact of tuberculosis therapy on nevirapine trough plasma concentrations. AIDS 1999, 13:2489-2490.
7. Ribera E, Pou L, Lopez RM, Crespo M, Falco V, Ocana I, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquired Immune Defic Syndr 2001, 28:450-453.
8. Robinson P, Lamson M, Gigliotti M. Pharmacokinetic interaction between nevirapin and rifampicin. In: XIIth International Conference on AIDS. Geneva, Switzerland, June 1998 [Abstract 60623].
9. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995, 171:537-545.